Major Growth Driver Identified in 2025 Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market: Growing Prevalence of Respiratory Diseases on COPD and Asthma Devices

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of devices for chronic obstructive pulmonary disease (copd) and asthma has seen significant expansion in the past few years. There is anticipated further development from $44.95 billion in 2024 to $47.56 billion in 2025, which translates to a compound annual growth rate (CAGR) of 5.8%. The surge during the previous period is linked to factors such as an aging population, heightened frequency of allergies, increased governmental efforts, a boost in clinical investigations and experiments, and urbanization expansion.

Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Size Forecast: What's the Projected Valuation by 2029?
The market for chronic obstructive pulmonary disease (COPD) and asthma devices is set to experience significant growth in the coming years. With a projected compound annual growth rate (CAGR) of 5.7%, it will attain a value of $59.46 billion by 2029. This growth projection for the forecast period owes to an increase in respiratory diseases, escalating cigarette smoking, surging environmental pollution, and respiratory issues, along with an increase in healthcare expenses and the portability of drug delivery devices. The anticipated trends within this period comprise technological progress, smart technology integration, individualized medicine, biologics adoption, and wearable respiratory monitors.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-and-asthma-devices-global-market-report

What Are the Drivers Transforming the Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?
The escalating instances of lung diseases are likely to drive the expansion of the market for devices related to chronic obstructive pulmonary disease (COPD) and asthma. These lung diseases include a range of conditions impacting the respiratory system, such as asthma, COPD, lung cancer, and pneumonia, which affect the person's ability to breathe and function of the respiratory system. The rise in lung diseases is attributed to high levels of air pollution, shifts in climate patterns that influence allergens and pathogens, and lifestyle habits like smoking that weaken respiratory health. COPD and asthma devices play a pivotal part in the all-encompassing management and treatment of respiratory diseases, aiding patients to maintain improved respiratory health and boost their overall well-being. For example, in March 2023, the World Health Organization (WHO), a specialized UN agency based in Switzerland, responsible for global public health, announced that COPD was the third major cause of death worldwide, leading to approximately 3.23 million fatalities. Furthermore, about 90% of these deaths among individuals below 70 years happened in low- and middle-income countries (LMICs). Consequently, the surge in respiratory diseases stimulates the growth of the COPD and asthma devices market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18298&type=smp

What Long-Term Trends Will Define the Future of the Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?
Leading corporations in the COPD and asthma devices market are concentrating on crafting innovative technologies like inhalation devices that merge with digital health characteristics for remote supervision and personalized treatment management. Inhalation devices, which administer medication directly into the lungs, are an example of such initiatives. For example, in May 2022, India's Alkem Laboratories launched the Innohaler, a dry powder inhaler (DPI) device aimed at making life easier for asthma and COPD patients. The Innohaler brings superior breath-actuated technology to the table, ensuring that each inhalation delivers precise medication, improving dosage precision, and decreasing wastage. It's user-friendly interface, coupled with its ergonomic design, simplifies operation for patients across all age groups. Moreover, the device's compact and portable design increases convenience for use on the move, thereby enhancing adherence to prescribed treatments for patients.

Which Segments in the Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market Offer the Most Profit Potential?
The chronic obstructive pulmonary disease (copd) and asthma devices market covered in this report is segmented -

1) By Type: Metered Dose Inhalers, Drug Powder Inhalers, Soft Mist Inhalers, Jet Nebulizers, Ultrasonic Nebulizers, Other Types
2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease
3) By Application: Hospitals, Clinics, Home Care Settings, Research Institutions, Other Applications
4) By End User: Pediatric, Adult, Geriatric

Subsegments:
1) By Metered Dose Inhalers: Conventional MDI, Breath-Actuated MDI
2) By Drug Powder Inhalers: Dry Powder Inhalers (DPI), Multi-Dose DPI
3) By Soft Mist Inhalers: Respimat Soft Mist Inhalers, Other Soft Mist Devices
4) By Jet Nebulizers: Pneumatic Nebulizers, Venturi-Type Nebulizers
5) By Ultrasonic Nebulizers: Tabletop Ultrasonic Nebulizers, Portable Ultrasonic Nebulizers
6) By Other Types: Nebulizer Accessories, Spacer Devices

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18298&type=smp

Which Firms Dominate the Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market by Market Share and Revenue in 2025?
Major companies operating in the chronic obstructive pulmonary disease (COPD) and asthma devices market are AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, 3M Health Care, Boehringer Ingelheim, Royal Philips NV, Teva Pharmaceuticals Industries Ltd., Baxter International Inc., Omron Corporation, Smiths Medical Inc., Recipharm AB, Cipla Ltd., Teleflex Incorporated, Chiesi Farmaceutici SpA, Lincre Holdings Inc., Sunovion Pharmaceuticals Inc., Verona Pharma plc, Drive DeVilbiss Healthcare, Pari Respiratory Equipment Inc., Allied Healthcare Products Inc., Clement Clarke International Ltd., Cohero Health Inc., Pneuma Respiratory Inc., Mundipharma International Ltd.

Which Regions Offer the Highest Growth Potential in the Chronic Obstructive Pulmonary Disease (COPD) And Asthma Devices Market?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) and asthma devices market in 2024. The regions covered in the chronic obstructive pulmonary disease (COPD) and asthma devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18298

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay,
Americas: +1 310-496-7795,
Asia: +44 7882 955267 & +91 8897263534,
Europe: +44 7882 955267,
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.